Abstract Number: PB0738
Meeting: ISTH 2021 Congress
Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide. The most common causes of HCC are hepatitis B or C virus infections, alcoholic liver disease, nonalcoholic fatty liver disease, biliary diseases, metabolic disorders, drugs, toxins, and genetic conditions. Chronic inflammation and consequent regeneration enhance mutagenesis in hepatocytes. The inflammation of hepatic cells results in the secretion of cytokines and chemokines as well as lysis of infected cells, which causes much of the liver injury. Interleukins (IL) are a group of cytokines that were first seen to be expressed by white blood cells and stimulate inflammation; this stimulation of the immune response by interleukins can lead to thrombosis.
Aims: The purpose of this study is to analyze different Interleukins, their concentration, and role in the development of thrombosis in HCC.
Methods: Citrated blood samples from 36 patients with confirmed diagnosis of HCC were collected from the hospital and frozen at -80C. Controlled plasma samples were comprised of 49 samples collected from normal healthy individuals. Biomarkers of inflammation including IL-1b, IL-2, IL-4, IL-6 and IL-10 were measured using commercially available kits (R&D laboratories, Minneapolis, MN). All results were compiled as mean + SEM.
Results: In comparison to normal subjects, patients with HCC showed variable increases in the parameters study. IL6 and 8 showed the most pronounced increase in comparison to other interleukins. There was no correlation between IL-6 and IL-8 levels.
Conclusions: These results demonstrate that interleukin levels are elevated in patients with ACC in comparison to normal samples IL-6 and IL-8 showed the most pronounced increase. This elevation of interleukins potentially contributes to the pathogenesis of HCC. Thus, interleukins provide a prognostic biomarker panel for HCC.
To cite this abstract in AMA style:Farooqui A, Kulkarni A, Hoppensteadt D, Van Thiel D, Siddiqui F, Fareed J. Biomarkers of Inflammation and Thrombosis in Hepatocellular Carcinoma [abstract]. Res Pract Thromb Haemost. 2021; 5 (Suppl 2). https://abstracts.isth.org/abstract/biomarkers-of-inflammation-and-thrombosis-in-hepatocellular-carcinoma/. Accessed November 29, 2021.
« Back to ISTH 2021 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/biomarkers-of-inflammation-and-thrombosis-in-hepatocellular-carcinoma/